Amgen and Onyx to present data at ASH 2013

Amgen and Onyx Pharmaceuticals have announced that they will be sharing data on their newest drug developments at the American Society of Hematology (ASH) annual meeting and exposition next month.

Running from December 7th to 10th in New Orleans, the event will see the companies presenting nearly 40 company and investigator-sponsored investigational studies on the second-generation proteasome inhibitors carfilzomib and oprozomib.

The data will demonstrate the potential benefits of these compounds in the treatment of multiple myeloma and haematologic malignancies, with results from the collaborative Prism NTP study programme to be discussed.

Dr Pablo Cagnoni, president of Onyx Pharmaceuticals, said: "We remain committed to bringing innovative therapies to patients in need and we look forward to playing a continued role in advancing the scientific understanding of haematologic malignancies."

This comes after Amgen completed a $9.7 billion (6.03 billion pounds) takeover of Onyx last month, a deal that will help to greatly strengthen its capabilities in the fields of cancer research and drug development.